Updated Data Matrix Available

Market Value | Market Volume | Epidemiology | Clinical Trials | Patent Landscape | Regulatory Approvals

Colorectal Cancer Drugs Market by Drug Class – Vascular Endothelial Growth Factor (VEGF) Inhibitors, Epidermal Growth Factor Receptor (EGFR) Inhibitors, Programmed Cell Death Protein 1/PD1 Ligand 1 (PD1/PDL1) Inhibitors, B-Raf Kinase (BRAF) or MEK Inhibitors – Mitogen-activated Protein Kinase (MAPK) / Extracellular Signal-Regulated Kinase (ERK), Tyrosine Kinase (TKI) Inhibitors, Immunomodulators, Chemotherapies and Forecast 2024-2031


Report Specifications: Market Size, Market Share, Growth Trends, Forecast, Geography

Colorectal cancer is the third leading cause of cancer-related deaths in women in the United States and the second leading cause in men. The death rate from colorectal cancer has been dropping in both men and women for several decades, mainly due to colorectal polyps screening and improved treatment over the last few decades.

Targeted therapy drugs for colorectal cancer include anti- vascular endothelial growth factor (VEGF) therapies that stops VEGF from forming new blood vessels and pass nutrients to tumor cells (also known as, anti-angiogenesis therapy). These include monoclonal antibody therapy such as, Bevacizumab (Avastin), Ramucirumab (Cyramza), Ziv-aflibercept (Zaltrap), and Ramucirumab (Cyramza). When combined with chemo, these drugs can often help patients with advanced colon or rectal cancers to live longer. Anti- epidermal growth factor receptor (EGFR) therapies target EGFR protein that often appears in high amounts on the surface of cancer cells and helps them grow. These include: Cetuximab (Erbitux), and Panitumumab (Vectibix). Regorafenib (Stivarga) is a type of targeted therapy known as a kinase inhibitor, used to treat advanced colorectal cancer. It blocks several kinase proteins that either help tumor cells grow or help form new blood vessels to feed the tumor. Blocking these proteins can help stop the growth of cancer cells. Immune checkpoint inhibitors such as Pembrolizumab (Keytruda) targets PD-1, a protein on immune system cells that normally prevents cells from attacking other cells in the body. Some common chemotherapy drugs used for colorectal cancer include: 5-Fluorouracil (5-FU), Capecitabine (Xeloda), Irinotecan (Camptosar), Oxaliplatin (Eloxatin), Trifluridine and tipiracil (Lonsurf). Dabrafenib and trametinib, the first BRAF and MEK inhibitor combination drugs are in clinical trials, and currently the FDA approved combination in patients with advanced mutated melanoma.

The global colorectal cancer drugs market segmentation is based on drug class – vascular endothelial growth factor (VEGF) inhibitors, epidermal growth factor receptor (EPGR) inhibitors, programmed cell death protein 1/PD1 ligand 1 (PD1/PDL1) inhibitors, B-Raf kinase (BRAF) or MEK inhibitors – mitogen-activated protein kinase (MAPK) / extracellular signal-regulated kinase (ERK), tyrosine kinase (TKI) inhibitors, immunomodulators, and chemotherapies.

The global colorectal cancer drugs market research report provides market size ($Million 2021 to 2031), market share analysis, growth trends and forecast (CAGR%, 2024 to 2031). The global colorectal cancer drugs market research report is further segmented by geography into North America (U.S., Canada), Latin America (Brazil, Mexico, Rest of LA), Europe (U.K., Germany, France, Italy, Spain, Rest of EU), Asia Pacific (Japan, China, India, Rest of APAC), and Rest of the World. In addition, the global colorectal cancer drugs market report provides the detailed market landscape (market drivers, restraints, opportunities), market attractiveness analysis, and market profitability analysis by key products and regions or countries.  The report also tracks the major competitors operating in the global market by company overview, financial snapshot, major products, technologies, services offered and recent developments.

Major players operating in the global colorectal cancer drugs market and profiled in this report include AB Science, Amgen, Array BioPharma, Bayer, Boehringer Ingelheim, Bristol-Myers Squibb, Elli Lilly, Genentech (Roche), Hutchison MediPharma, Merck & Co., Mologen, Regeneron, Sanofi, Sumitomo Dainippon, Taiho Pharmaceutical, and Vaccinogen.

DATA INCLUDED: Colorectal Cancer Drugs Market Size, Colorectal Cancer Drugs Market Share, Colorectal Cancer Drugs Market Growth Rates, Colorectal Cancer Drugs Market Trends, and Colorectal Cancer Drugs Market Forecast to 2031

Market Data:

  • Base year for estimation: 2023
  • Actual estimates/Historical data: 2021-2031
  • Forecast period: 2024-2031
  • Market representation: Revenue in $million and CAGR % from 2024 to 2031
  • Regional scope: North America, Europe, Asia Pacific, Latin America, Rest of the World (Middle East & Africa)
  • Country scope: U.S., Canada, U.K., Germany, France, Italy, Spain, Japan, China, India, South Korea, Brazil, Mexico, South Africa, South Korea, Saudi Arabia, UAE and others.
  • Report coverage: Revenue forecast, company share, competitive landscape, growth factors, and trends
  • 15% free customization scope: Any specific or custom requirements, which is not currently within the scope of the report, will be provided as a part of customization.

Qualitative Analysis:

  • Industry overview
  • Industry trends
  • Market drivers and restraints
  • Key market opportunities
  • Market size
  • Growth trends
  • Porter’s five forces analysis
  • Market attractiveness analysis
  • Competitive landscape
    • Company overview
    • Financial performance
    • Product portfolio
    • Strategic insights
    • Recent developments

Quantitative Analysis:

  • Market size estimates and forecast for all segments
  • Regional market size estimated and forecast for major countries
  • Company financial performance
  • Competitive landscape: Company market share analysis

Please contact us for offers on individual or multiple report purchases.

  1. Introduction
  2. Executive Summary
    • Market Size Estimation ($million, 2021-2031)
    • Forecast Estimation ($million and CAGR%, 2024-2031)
  3. Research Methodology
  4. Market Landscape
    • Market Dynamics
      • Drivers
      • Barriers
      • Opportunities
    • Market Share Analysis
      • Companies
      • Drugs
    • Market Trends Analysis
      • Key success factors
      • Market Growth Rate
    • Market Attractiveness Analysis
    • Market Profitability Analysis
      • Buyer power
      • Supplier power
      • Barriers to entry
      • Threat of substitute products
      • Rivalry among firms in the industry
    • Distribution Channels
  5. Market Segmentation [refer Market Segments and Companies Tab]
    • Drug Class or Drug (Brand) Type
    • Drug or Disorder Test
    • Indication Type
    • Drug Treatment
    • Mechanism of Action
    • Therapeutic Area or Nature of Application
    • End User Groups
  6. Geography (Region, Country)
    • North America (U.S., Canada)
    • Europe (U.K., Germany, France, Italy, Spain, Rest of EU)
    • Asia Pacific (Japan, China, India, Rest of APAC)
    • Latin America (Brazil, Mexico, Rest of LA)
    • Rest of the World (Middle East & Africa)
  7. Regulatory Overview 
    • IND, NDA filed, FDA, EMEA Approvals
  8. Pipeline Analysis(Phase 1, 2 and 3 Drugs)
    • Phase 3 Drugs Forecast Estimation (Approval to 2031)
    • Phase 1 and 2 Drugs – Qualitative Analysis
  9. Company Profiles [refer Market Segments and Companies Tab]
    • Company Overview
    • Financial Snapshot
    • Product Portfolio
    • Business Strategies
    • Recent Developments
  10. Recommendations
  11. References

Key Questions Answered:
1. What are the factors driving and limiting this market, key success factors and challenges?
2. Which are the leading competitors in the market, their market share, profitability and key trends by product, technology, services portfolio?
3. How do markets perform between countries and regions?
4. What market segments are contributing to maximum share and greatest growth?
5. What are the product or procedure volumes by country and regions?

Actionable Insights Included:
1. Product portfolio matrix (Share vs. Growth)
2. Market attractiveness (Region vs. Growth)
3. Spot matrix (Product vs. Region)
4. Geographic distribution matrix (Share vs. Growth)

Colorectal Cancer Drugs Market

1. Drug Class
1.1. Vascular Endothelial Growth Factor (VEGF) Inhibitors
1.2. Epidermal Growth Factor Receptor (EGFR) Inhibitors
1.3. Programmed Cell Death Protein 1/PD1 Ligand 1 (PD1/PDL1) Inhibitors
1.4. BRAF or MEK Inhibitors (MAPK/ERK kinase)
1.5. Tyrosine Kinase (TKI) Inhibitors
1.6. Immunomodulators
1.7. Chemotherapies

2. Geography
2.1. North America (U.S., Canada)
2.2. Latin America (Brazil, Mexico, Rest of LA)
2.3. Europe (U.K., Germany, France, Italy, Spain, Rest of EU)
2.4. Asia Pacific (Japan, China, India, Rest of APAC
2.5. Rest of the World

3. Company Profiles
3.1. AB Science
3.2. Amgen
3.3. Array BioPharma
3.4. Bayer
3.5. Boehringer Ingelheim
3.6. Bristol-Myers Squibb
3.7. Elli Lilly
3.8. Genentech (Roche)
3.9. Hutchison MediPharma
3.10. Merck & Co.
3.11. Mologen
3.12. Regeneron
3.13. Sanofi
3.14. Sumitomo Dainippon
3.15. Taiho Pharmaceutical
3.16. Vaccinogen

    Request ToC / Sample Report

    Full Name*

    Company Email*

    Phone Number* [Please add country code]



    Secure Online Payment

    iHealthcareAnalyst, Inc.

    Contact Address

    US Office: 2109, Mckelvey Hill Drive, Maryland Heights, MO 63043, United States
    Phone: +1 (314) 315-4764
    India Office: 5, Shilpa Chambers, Opp. J. M. Road, Shivajinager, Pune 411005, India
    Phone: +91 (20) 25898524
    Email: sales@ihealthcareanalyst.com